Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro and in Vivo Antistaphylococcal Activity Determination of the New Recombinant Lysostaphin Protein

Hamid Abtahi 1 , Leila Farhangnia 2 and Ehsanollah Ghaznavi-Rad 3 , *
Authors Information
1 Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, IR Iran
2 Department of Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, IR Iran
3 Department of Microbiology and Immunology, Molecular and Medicine Research Center, Faculty of Medicine, Arak University of Medical Sciences, Arak, IR Iran
Article information
  • Jundishapur Journal of Microbiology: March 01, 2016, 9 (3); e28489
  • Published Online: March 2, 2016
  • Article Type: Research Article
  • Received: March 7, 2015
  • Revised: May 31, 2015
  • Accepted: June 14, 2015
  • DOI: 10.5812/jjm.28489

To Cite: Abtahi H, Farhangnia L, Ghaznavi-Rad E. In Vitro and in Vivo Antistaphylococcal Activity Determination of the New Recombinant Lysostaphin Protein, Jundishapur J Microbiol. 2016 ; 9(3):e28489. doi: 10.5812/jjm.28489.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339(8): 520-32[DOI][PubMed]
  • 2. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1996; 24(5): 380-8[PubMed]
  • 3. Kumar JK. Lysostaphin: an antistaphylococcal agent. Appl Microbiol Biotechnol. 2008; 80(4): 555-61[DOI][PubMed]
  • 4. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev. 1963; 27: 56-71[PubMed]
  • 5. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997; 10(3): 505-20[PubMed]
  • 6. Goslings WR, Buchli K. Nasal carrier rate of antibiotic-resistant staphylococci; influence of hospitalization on carrier rate in patients, and their household contacts. AMA Arch Intern Med. 1958; 102(5): 691-715[PubMed]
  • 7. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002; 346(24): 1871-7[DOI][PubMed]
  • 8. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001; 344(1): 11-6[DOI][PubMed]
  • 9. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, Bogaers-Hofman D, de Baere GA, Stuurman A, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis. 2002; 35(4): 353-8[DOI][PubMed]
  • 10. Bannerman TL, Peacock SJ, Murray PR, Baron EJ, Jorgensen JH, Landry ML, et al. Staphylococcus, Micrococcus, and other catalase-positive cocci. Man Clin Microbiol. 2006; 1: 390-411
  • 11. Schindler CA, Schuhardt VT. Lysostaphin: A New Bacteriolytic Agent for the Staphylococcus. Proc Natl Acad Sci. 1964; 51(3): 414-21[DOI]
  • 12. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 2003; 47(11): 3407-14[PubMed]
  • 13. Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci. 2000; 41(6): 1432-7[PubMed]
  • 14. Patron RL, Climo MW, Goldstein BP, Archer GL. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 1999; 43(7): 1754-5[PubMed]
  • 15. Bhakta M, Arora S, Bal M. Intraspecies transfer of a chloramphenicol-resistance plasmid of staphylococcal origin. Indian J Med Res. 2003; 117: 146-51[PubMed]
  • 16. Bastos M, Coutinho BG, Coelho MLV. Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals. 2010; 3(4): 1139-61[DOI]
  • 17. Farhangnia L, Ghaznavi-Rad E, Mollaee N, Abtahi H. Cloning, Expression, and Purification of Recombinant Lysostaphin From Staphylococcus simulans. Jundishapur J Microbiol. 2014; 7(5)[DOI][PubMed]
  • 18. Satishkumar R, Sankar S, Yurko Y, Lincourt A, Shipp J, Heniford BT, et al. Evaluation of the antimicrobial activity of lysostaphin-coated hernia repair meshes. Antimicrob Agents Chemother. 2011; 55(9): 4379-85[DOI][PubMed]
  • 19. Kiser KB, Cantey-Kiser JM, Lee JC. Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect Immun. 1999; 67(10): 5001-6[PubMed]
  • 20. Schaffer AC, Solinga RM, Cocchiaro J, Portoles M, Kiser KB, Risley A, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun. 2006; 74(4): 2145-53[DOI][PubMed]
  • 21. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother. 2003; 47(5): 1589-97[PubMed]
  • 22. Klesius PH, Schuhardt VT. Use of lysostaphin in the isolation of highly polymerized deoxyribonucleic acid and in the taxonomy of aerobic Micrococcaceae. J Bacteriol. 1968; 95(3): 739-43[PubMed]
  • 23. Geary C, Stevens M. Rapid lysostaphin test to differentiate Staphylococcus and Micrococcus species. J Clin Microbiol. 1986; 23(6): 1044-5[PubMed]
  • 24. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 1995; 31(1): 13-24[PubMed]
  • 25. Quickel KJ, Selden R, Caldwell JR, Nora NF, Schaffner W. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbiol. 1971; 22(3): 446-50[PubMed]
  • 26. Faith RE, Montgomery CA, Durfee WJ, Aguilar-Cordova E, Wyde PR. The cotton rat in biomedical research. Lab Anim Sci. 1997; 47(4): 337-45[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments